OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
MedPharm has received a multi-million dollar investment by Ampersand Capital Partners to diversify its service offering and regional coverage.
MedPharm, a provider of contract topical and transdermal product design and formulation development services, announced on Mar. 26, 2018 that it has received a multi-million dollar investment by Ampersand Capital Partners. Founded 20 years ago, MedPharm’s services currently encompass formulation development, performance testing, and clinical trials manufacturing at its facilities in Guildford, UK and Durham, NC, US.
Dr. Andrew Muddle, co-founder and CEO of MedPharm, said in a press statement, “We are excited to partner with Ampersand to diversify MedPharm’s service offering and regional coverage. We look forward to growing the business together for the benefit of our customers.”
Professor Marc Brown, co-founder and CSO of MedPharm, commented, “We have chosen to partner with Ampersand at an opportune time. Ampersand’s investment will help us respond to strong market demand for MedPharm’s services whilst maintaining our core values of scientific integrity, innovation, and flexibility.”
Ampersand general partner David Parker noted that MedPharm fits Ampersand’s strategy of investing in growth-oriented businesses that have established leadership positions in specialty segments of the contract development and manufacturing organization space. “We are thrilled to have the opportunity to partner with MedPharm’s management team to drive future growth and success of the business,” he said.